CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022

Rhea-AI Summary

CTI BioPharma (NASDAQ: CTIC) announced it will report its second quarter 2022 financial results on August 8, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET for a corporate update. Additionally, the company will participate in key biotechnology conferences, including the BTIG Biotechnology Conference on August 9 and the Stifel Biotech Summer Summit on August 16.

CTI BioPharma focuses on developing therapies for blood-related cancers and has an FDA-approved product, VONJO, for treating myelofibrosis.

– Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit –

SEATTLE, Aug. 1, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

To access the live call by phone please dial (888) 317-6003 (domestic) or (412) 317-6061 (international); the conference ID is 0078819. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

August Conferences
CTI BioPharma also announced that it will participate in one-on-one meetings at the BTIG Biotechnology Conference on August 9, 2022. Additionally, the Company will participate in a fireside chat and one-on-one meetings at the Stifel Biotech Summer Summit on Tuesday, August 16, 2022, at 11:00 am E.T.

The Stifel fireside chat will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^® (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^® is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-second-quarter-2022-financial-results-on-august-8-2022-301596903.html

SOURCE CTI BioPharma Corp.

FAQ

When will CTI BioPharma report its Q2 2022 financial results?

CTI BioPharma will report its second quarter 2022 financial results on August 8, 2022, after market close.

What conferences will CTI BioPharma participate in August 2022?

CTI BioPharma will participate in the BTIG Biotechnology Conference on August 9, 2022, and the Stifel Biotech Summer Summit on August 16, 2022.

What is VONJO and its indication?

VONJO is an FDA-approved treatment for adults with intermediate or high-risk myelofibrosis and severe thrombocytopenia.

What is the significance of the PACIFICA study for CTI BioPharma?

The PACIFICA study is a Phase 3 trial for VONJO, fulfilling a post-marketing requirement to confirm clinical benefits.